TipRanks
Advertisement
Advertisement

DE:0OT Stock Latest News

Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
RatingsOcular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
10d ago
OCUL
Ocular Therapeutix falls -18.2%
PremiumThe Fly
Ocular Therapeutix falls -18.2%
10d ago
OCUL
Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results
PremiumThe Fly
Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results
10d ago
FDMT
OCUL
Ocular Therapeutix falls -18.1%
PremiumThe Fly
Ocular Therapeutix falls -18.1%
10d ago
OCUL
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
PremiumRatings
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
13d ago
OCUL
Ocular Therapeutix management to meet with Piper Sandler
PremiumThe FlyOcular Therapeutix management to meet with Piper Sandler
15d ago
OCUL
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
Premium
Ratings
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
22d ago
OCUL
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
Premium
Ratings
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
22d ago
OCUL
Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli
PremiumThe Fly
Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli
23d ago
OCUL
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
PremiumRatings
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
2M ago
OCUL
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
PremiumRatings
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
2M ago
OCUL
Clear Street sees less competition for Ocular after EyePoint miss
PremiumThe Fly
Clear Street sees less competition for Ocular after EyePoint miss
2M ago
EYPT
OCUL
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
PremiumRatingsOcular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
2M ago
OCUL
Ocular Therapeutix rises 10.4%
Premium
The Fly
Ocular Therapeutix rises 10.4%
2M ago
OCUL
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
Premium
Company Announcements
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
2M ago
OCUL
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
PremiumRatings
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
2M ago
OCUL
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
PremiumThe Fly
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
2M ago
OCUL
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
3M ago
P
CW
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
PremiumThe Fly
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
4M ago
OCUL
Ocular Therapeutix price target raised to $30 from $24 at Baird
PremiumThe FlyOcular Therapeutix price target raised to $30 from $24 at Baird
4M ago
OCUL
Ocular Therapeutix trading resumes
Premium
The Fly
Ocular Therapeutix trading resumes
4M ago
OCUL
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
Premium
The Fly
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
4M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >